Phase II study of Troxatyl ™ in patients with chronic myeloid leukemia in blastic phase (CML-BP).

被引：0
|
作者：
Giles, F
Feldman, E
Cortes, J
Faderl, S
Larson, R
Mamus, S
Thomas, D
Garcia-Manero, G
O'Brien, S
Beran, M
Talpaz, M
Kantarjian, H
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Cornell Univ, New York, NY USA
[3] Univ Chicago, Canc Res Ctr, Chicago, IL USA
[4] Univ Texas, MD Anderson Canc Ctr, Orlando, FL USA
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4764
引用
收藏
页码：258B / 258B
页数：1
相关论文
共 50 条
  • [31] Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia
    Oki, Yasuhiro
    Kantarjian, Hagop M.
    Gharibyan, Vazganush
    Jones, Dan
    O'Brien, Susan
    Verstovsek, Srdan
    Cortes, Jorge
    Morris, Gail M.
    Garcia-Manero, Guillermo
    Issa, Jean-Pierre J.
    CANCER, 2007, 109 (05) : 899 - 906
  • [32] BCL-2 EXPRESSION IN-VIVO IN ACUTE MYELOID-LEUKEMIA (AML), CHRONIC PHASE CML, AND MYELOID BLASTIC CRISIS OF CML
    PREISLER, HD
    HEGDE, U
    BLOOD, 1993, 82 (10) : A111 - A111
  • [33] Results of a Phase II Trial of Dasatinib As Frontline Therapy for Chronic Myeloid Leukemia (CML) In Chronic Phase (CP)
    Pemmaraju, Naveen
    Kantarjian, Hagop M.
    Luthra, Rajyalakshmi
    O'Brien, Susan
    Jabbour, Elias
    Quintas-Cardama, Alfonso
    Borthakur, Gautam
    Ravandi, Farhad
    Verstovsek, Srdan
    Burton, Elizabeth
    Walker, Brenda
    Cortes, Jorge E.
    BLOOD, 2011, 118 (21) : 740 - 741
  • [34] DIFFERENTIATION PATTERNS IN THE BLASTIC PHASE OF CHRONIC MYELOID-LEUKEMIA
    GRIFFIN, JD
    TODD, RF
    RITZ, J
    NADLER, LM
    CANELLOS, GP
    ROSENTHAL, D
    GALLIVAN, M
    BEVERIDGE, RP
    WEINSTEIN, H
    KARP, D
    SCHLOSSMAN, SF
    BLOOD, 1983, 61 (01) : 85 - 91
  • [35] A phase II study of intravenous (IV) homoharringtonine (HUT) and imatinib (IM) in patients (pts) with chronic myeloid leukemia (CML).
    Quintas-Cardama, Alfonso
    Kantarjian, Hagop M.
    Wierda, William
    Ferrajoli, Alessandra
    Chen, Rong
    Ravandi, Farhad
    Plunkett, William
    Cortes, Jorge
    BLOOD, 2006, 108 (11) : 616A - 617A
  • [36] CAN CHROMOSOMES PREDICT DRUG SENSITIVITY IN BLASTIC PHASE CHRONIC MYELOGENOUS LEUKEMIA (CML) PATIENTS
    MARINELLO, M
    EARLY, A
    PREISLER, H
    DOEBLIN, T
    BANNEMAN, R
    AMERICAN JOURNAL OF HUMAN GENETICS, 1983, 35 (06) : A67 - A67
  • [37] Phase 2 Study of Dasatinib with and without Venetoclax in Patients with Early Chronic Phase Chronic Myeloid Leukemia (ECP-CML)
    Haddad, Fadi G.
    Jabbour, Elias
    Sasaki, Koji
    Nasr, Lewis
    Huang, Xuelin
    Issa, Ghayas C.
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Kadia, Tapan M.
    Daver, Naval
    Valero, Yesid Alvarado
    Nasnas, Cedric
    Ohanian, Maro
    Short, Nicholas J.
    Masarova, Lucia
    Zoghbi, Marianne
    Nasnas, Patrice Eric
    Montalban-Bravo, Guillermo
    Skinner, Jeffrey
    Pierce, Sherry
    Andreeff, Michael
    Kantarjian, Hagop M.
    BLOOD, 2023, 142
  • [38] Phase II study of Mylotarg plus Troxatyl in patients with refractory acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS).
    Giles, FJ
    Garcia-Manero, G
    O'Brien, S
    Estey, E
    Kantarjian, H
    BLOOD, 2001, 98 (11) : 212B - 212B
  • [39] Study of tumor cells immunophenotype in chronic phase (CP) of chronic myeloid leukemia (CML).
    Logacheva, NP
    Turkina, AG
    Shishkin, YV
    Zabotina, TN
    Baryshnikov, AY
    LEUKEMIA, 2001, 15 (03) : 504 - 504
  • [40] Hypercvad Plus Imatinib or Dasatinib for Patients with Lymphoid Blastic Phase of Chronic Myeloid Leukemia
    Strati, Paolo
    Kantarjian, Hagop M.
    Thomas, Deborah A.
    O'Brien, Susan M.
    Jabbour, Elias J.
    Quintas-Cardama, Alfonso
    Borthakur, Gautam
    Faderl, Stefan
    Ravandi, Farhad
    Cortes, Jorge E.
    BLOOD, 2012, 120 (21)
12345